NEW YORK (GenomeWeb News) — Exosome Diagnostics said today that it has closed a Series B financing round raising $27 million.

New York-based Exosome will use the proceeds of the financing to advance development of its proprietary platform technology for preparing nucleic acids from microvesicles, as well commercial programs for non-invasive, fluid-based molecular diagnostics in oncology, neurodegenerative disease, and other clinical areas.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.